Diagnosing Health Care Podcast

On April 21, 2023, the U.S. Supreme Court ruled to preserve access to the prescription abortion drug mifepristone. However, while the case continues in the U.S. Court of Appeals for the Fifth Circuit, the future of mifepristone—and the U.S. Food and Drug Administration’s authority to approve new drugs—will continue to be debated on appeal. On this episode,...

The Inflation Reduction Act (IRA), signed into law in August 2022, included significant and controversial drug-pricing provisions. What key compliance issues must industry stakeholders consider as these provisions are put into effect? On this episode, Epstein Becker Green attorneys Leslie Norwalk, Connie Wilkinson, a...

A complex landscape of state laws overlays the direct access testing model, ranging from physician order requirements, such as telemedicine standards and the corporate practice of medicine doctrine, to specimen collection considerations, including how the varying options for collection could impact a model. How do these factors combine to create a roadmap f...

Renewed interest in the potential benefits of psychedelic treatments has led to an upsurge in research. Is the first FDA approval of a psychedelic for therapeutic use on the horizon? On this episode, Epstein Becker Green attorneys Delia Deschaine, Lisa Gora, and Jessika Tuazon

The Federal Reserve's steady increase of interest rates and the slowed economic growth have increased fiscal pressure on health care providers, leaving many to look for ways to bridge budget shortfalls through injections of capital, asset sales, or other strategic transactions. What options are there for providers moving forward? On this episode, Epstein B...

In conjunction with the national COVID-19 public health emergency (PHE), the Centers for Medicare & Medicaid Services and other federal agencies have issued waivers and other declarations with the goal of giving providers flexibility in order to render services during the PHE. How should stakeholders prepare for the end of the PHE on May 11, 2023? On this episode, Eps...

When analyzing the lifecycle of any health care product, a key component to consider is how much the product will cost and who will pay for it. What unique challenges do direct access tests pose when it comes to reimbursement and related compliance requirements? On the second episode of our four-part series on direct access laboratory testing, Epstein Beck...

What are the various factors impacting stakeholders in the direct access testing industry? By the end of this four-part series on direct access laboratory testing, listeners will have gained insight into how to navigate the complex regulatory and legal regimes that govern the process of making lab tests available directly to patients and understand the asp...

The U.S. Food and Drug Administration (FDA) recently issued a final guidance document clarifying how the agency intends to regulate clinical decision support software (CDS). How has this document caused confusion for industry? How can companies respond? On this episode, Epstein Becker Green attorneys Brad Thompson and

Changes are on the horizon for provisions of the Program of All-Inclusive Care for the Elderly (PACE) that haven't been updated in over a decade. What exactly is PACE and how will new proposed rule modifications affect PACE plans moving forward? On this episode, special guest Wendy Edwards, Director of Internal Operations at Bl...

The Dobbs v. Jackson Women's Health Organization decision, which effectively removed the federal constitutional protections for abortion, triggered a series of changes for health care providers and patients alike across the nation with respect to abortion services. What additional implications are there for certain ...

With the recent midterm elections changing the composition of Congress, and the Biden administration's first opportunities to advance its policy priorities from the very beginning of the rulemaking process, what are the key health care developments to watch out for in 2023? On this episode, Epstein Becker Green attorneys Ted Kennedy, Jr., Alexis Boaz, and Philo Hall discuss the current landscape of health care policy from both the ...

In the aftermath of the Dobbs v. Jackson Women's Health Organization decision, important questions have emerged about the current legal and regulatory landscape surrounding patient access to drugs that have historically been used to induce abortions. How can health care providers and pharmacies navigate these new restrictions? On this episode, Epstein Becker Green attorneys Delia Deschaine, Spreeha Choudhury, and Jessika Tuazon dis...

The past three years have been tumultuous in the health care construction economy, and the patterns in recent construction claims might surprise some. Which types of claims are popping up, in what regions are they appearing, and what types of facilities are involved? On this episode of our Owner's Outlook series, special guest Brett Lamb, co-founder and CEO of Construction Discovery Experts, and construction attorney Chris Dunn ana...

Following the Supreme Court's decision in Dobbs v. Jackson Women's Health Organization, some states have banned abortion in all or most circumstances and many more have enacted new restrictions or enforced old ones. What must providers and health care leaders understand about this patchwork of laws, the ongoing enforcement activity, and protecting their organization's interests? On this episode, Epstein Becker Green attorneys Jenny...

In celebration of the 50th episode of our Diagnosing Health Care podcast, we're looking at how the past 50 years of health law will impact health care in the next 50 years. On this episode, Epstein Becker Green attorneys Mark Lutes; Lynn Shapiro Snyder; Ted Kennedy, Jr.; and Nivedita Patel talk about the past, present, and future solutions to a fundamental question: How can the United States manage health care spending while contin...

While the COVID-19 pandemic seems to be moving into our rearview mirror, government investigations and enforcement actions targeting COVID-19-related fraud are just starting to heat up. What can businesses do to prevent or mitigate potential civil and criminal charges in this area? On this episode, Epstein Becker Green attorneys Melissa Jampol, Erica Sibley Bahnsen, and Rachel Weisblatt discuss COVID-19 relief funding programs that...

Since the beginning of 2022, prices for construction services and materials have seen significant increases. How have these increases impacted the advancement of both new and ongoing health care construction projects? On this episode of our Owner's Outlook series, Clint Russell, Vice President at HCA Healthcare, and construction attorney Chris Dunn talk about where costs are increasing, what might lie ahead, and how owners and prov...

The COVID-19 pandemic kicked off a pivot in health care construction and design, and acute care facilities have been rapidly renovating to adapt their spaces to evolving public health care needs. On this episode of our Owner's Outlook series, attorneys Chris Dunn and David Johnston discuss how owners could see unintended consequences from designing projects without the input of skilled regulatory compliance professionals or sound c...